PROKIDNEY CORP. (PROK) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74291D1046
PROKIDNEY CORP. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 893,000.00 USD |
| Operating income | -165.01 m USD |
| EBIT | -68.57 m USD |
| Net income | -68.99 m USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PROKIDNEY CORP.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
More stocks
- Catalyst Bancorp, Inc. (CLST)
- Ibkimyoung Co. Ltd (339950.KQ)
- VERDE RESOURCES, INC. (VRDR)
- Arch Meter Corporation (4588.TW)
- Sungmoon Electronics Co Ltd (014915.KS)
- Shanghai Huili Building Materials Co Ltd (900939.SS)
- Calisa Acquisition Corp (ALIS)
- Family International Gourmet Co., Ltd (7708.TWO)
- Caravel Minerals Ltd (CVV.AX)
- Atlas Energy Public Company Limited (ATLAS.BK)
- Elite Express Holding Inc. (ETS)
- AmpliTech Group, Inc. (AMPG)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.